PatientsHCPs
This site is for US Health Care Professionals only

LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1

.

Not an actual patient.

*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).3

.

†Greater LDL-C reduction was maintained during each 6-month dosing interval vs placebo as a complement to a maximally tolerated statin.1

.

Actor portrayal.

After a CV event, reaching and remaining at LDL-C target is critical4

SEE WHY

CAD, coronary artery disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.

.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C).

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 3. Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; July 10, 2023. 4. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018 Sep 4;72(10):1141-1156. doi: 10.1016/j.jacc.2018.06.046. PMID: 30165986.